The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement

Zhang, Hanwen; Yao, Longping; Zheng, Zijian; Koc, Sumeyye; Lu, Guohui

doi:10.3390/ph15070811

Cited by 21 publications

(15 citation statements)

References 251 publications

(240 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, in recent years, ncRNAs have become key molecules implicated in almost every process leading to the onset and progression of NDDs. The association between ncRNAs and disease pathogenesis has also been suggested in Parkinson’s disease (PD) [ 11 ], Huntington’s disease (HD) [ 12 ], Alzheimer’s disease (AD) [ 13 ], and other neurodegenerative disorders [ 14 ]. Overall, six major ncRNA-mediated mechanisms are likely to contribute to the neurodegenerative process: epigenetic regulation, regulation of gene expression by RNA interference (RNAi), alternative splicing, mRNA stability, translation regulation, and molecular snare [ 15 ].…”

Section: The Role Of Ncrnas In Neurodegenerative Diseasesmentioning

confidence: 99%

The Role of miR-128 in Neurodegenerative Diseases

Lanza

Cuzzocrea

Oddo

et al. 2023

IJMS

View full text Add to dashboard Cite

Several neurodegenerative disorders are characterized by the accumulation of misfolded proteins and are collectively known as proteinopathies. Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD) represent some of the most common neurodegenerative disorders whose steady increase in prevalence is having a major socio-economic impact on our society. Multiple laboratories have reported hundreds of changes in gene expression in selective brain regions of AD, PD, and HD brains. While the mechanisms underlying these changes remain an active area of investigation, alterations in the expression of noncoding RNAs, which are common in AD, PD, and HD, may account for some of the changes in gene expression in proteinopathies. In this review, we discuss the role of miR-128, which is highly expressed in mammalian brains, in AD, PD, and HD. We highlight how alterations in miR-128 may account, at least in part, for the gene expression changes associated with proteinopathies. Indeed, miR-128 is involved, among other things, in the regulation of neuronal plasticity, cytoskeletal organization, and neuronal death, events linked to various proteinopathies. For example, reducing the expression of miR-128 in a mouse model of AD ameliorates cognitive deficits and reduces neuropathology. Overall, the data in the literature suggest that targeting miR-128 might be beneficial to mitigate the behavioral phenotype associated with these diseases.

show abstract

Section: The Role Of Ncrnas In Neurodegenerative Diseasesmentioning

confidence: 99%

The Role of miR-128 in Neurodegenerative Diseases

Lanza

Cuzzocrea

Oddo

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Epigenetic regulatory interactions are not limited to the three mechanisms described above, but other options are far less studied. Still, a possible role in the pathogenesis of PD has been shown for histone modifications [95], circular RNAs (circRNAs), and competing endogenous RNAs (ceRNA) [96]. Analysis of the epigenetic profile in PD should be expanded to include new models of the disease, both cellular and organismal.…”

Section: Epigenetic Factors In the Development Of Parkinson's Diseasementioning

confidence: 99%

Genetic Architecture of Parkinson’s Disease

Шадрина

Slominsky

2023

Biochemistry Moscow

View full text Add to dashboard Cite

Year 2022 marks 25 years since the first mutation in familial autosomal dominant Parkinson’s disease was identified. Over the years, our understanding of the role of genetic factors in the pathogenesis of familial and idiopathic forms of Parkinson’s disease has expanded significantly – a number of genes for the familial form of the disease have been identified, and DNA markers for an increased risk of developing its sporadic form have been found. But, despite all the success achieved, we are far from an accurate assessment of the contribution of genetic and, even more so, epigenetic factors to the disease development. The review summarizes the information accumulated to date on the genetic architecture of Parkinson’s disease and formulates issues that need to be addressed, which are primarily related to the assessment of epigenetic factors in the disease pathogenesis.

show abstract

“…MicroRNAs (miRNAs) are endogenous small (18-25 nucleotides), single-stranded, non-coding RNAs that are playing a key role in post-transcriptional regulation of gene expression. Recently, different types of miRNA are considered to play a role in pathophysiology of PD (40), therefore significant effort was focused on identification and validation of miRNAs that can serve as biomarker of PD.…”

Section: Micrornasmentioning

confidence: 99%

Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods

Račay¹

2023

Acta Medica Martiniana

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a chronic neurodegenerative disorder that is clinically manifested by motor and non-motor symptoms. At the early stage of the disease, it can be misdiagnosed with some neurologic disorders due to overlapping or similar clinical features. In addition, the pathogenesis of this disease is initiated several years prior to the appearance of classical motor symptoms. This latent phase of neurodegeneration in PD characterised at cellular level by preservation of significant fraction of dopaminergic neurones is of particular interest with respect to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease with an aim to slow down or reverse the disease progression. Therefore, huge effort was performed in order to find and validate a biomarker that would reliably differentiate PD from other neurologic diseases as well as a biomarker that would reveal preclinical/prodromal stage of PD. This short review summarises a recent progress in validation of molecular biomarkers of PD, distinct from genetic markers of PD, with some focus on new analysed tissues and new methods.

show abstract

The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement

Cited by 21 publications

References 251 publications

The Role of miR-128 in Neurodegenerative Diseases

The Role of miR-128 in Neurodegenerative Diseases

Genetic Architecture of Parkinson’s Disease

Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods

Contact Info

Product

Resources

About